701 related articles for article (PubMed ID: 15577851)
1. Rebound eosinophilia after treatment of hypereosinophilic syndrome and eosinophilic gastroenteritis with monoclonal anti-IL-5 antibody SCH55700.
Kim YJ; Prussin C; Martin B; Law MA; Haverty TP; Nutman TB; Klion AD
J Allergy Clin Immunol; 2004 Dec; 114(6):1449-55. PubMed ID: 15577851
[TBL] [Abstract][Full Text] [Related]
2. Interleukin-5 and the posttreatment eosinophilia in patients with onchocerciasis.
Limaye AP; Abrams JS; Silver JE; Awadzi K; Francis HF; Ottesen EA; Nutman TB
J Clin Invest; 1991 Oct; 88(4):1418-21. PubMed ID: 1918387
[TBL] [Abstract][Full Text] [Related]
3. A review of treatment with mepolizumab, an anti-IL-5 mAb, in hypereosinophilic syndromes and asthma.
Busse WW; Ring J; Huss-Marp J; Kahn JE
J Allergy Clin Immunol; 2010 Apr; 125(4):803-13. PubMed ID: 20371394
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of the monoclonal anti-interleukin-5 antibody SCH55700 in the treatment of patients with hypereosinophilic syndrome.
Klion AD; Law MA; Noel P; Kim YJ; Haverty TP; Nutman TB
Blood; 2004 Apr; 103(8):2939-41. PubMed ID: 15070668
[TBL] [Abstract][Full Text] [Related]
5. Anti-IL-5 and hypereosinophilic syndromes.
Sutton SA; Assa'ad AH; Rothenberg ME
Clin Immunol; 2005 Apr; 115(1):51-60. PubMed ID: 15870021
[TBL] [Abstract][Full Text] [Related]
6. Anti-interleukin-5 antibody therapy in eosinophilic diseases.
Simon D; Braathen LR; Simon HU
Pathobiology; 2005; 72(6):287-92. PubMed ID: 16582580
[TBL] [Abstract][Full Text] [Related]
7. Preclinical efficacy and safety of mepolizumab (SB-240563), a humanized monoclonal antibody to IL-5, in cynomolgus monkeys.
Hart TK; Cook RM; Zia-Amirhosseini P; Minthorn E; Sellers TS; Maleeff BE; Eustis S; Schwartz LW; Tsui P; Appelbaum ER; Martin EC; Bugelski PJ; Herzyk DJ
J Allergy Clin Immunol; 2001 Aug; 108(2):250-7. PubMed ID: 11496242
[TBL] [Abstract][Full Text] [Related]
8. Anti-IL-5 (mepolizumab) therapy for eosinophilic esophagitis.
Stein ML; Collins MH; Villanueva JM; Kushner JP; Putnam PE; Buckmeier BK; Filipovich AH; Assa'ad AH; Rothenberg ME
J Allergy Clin Immunol; 2006 Dec; 118(6):1312-9. PubMed ID: 17157662
[TBL] [Abstract][Full Text] [Related]
9. Anti-interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes.
Garrett JK; Jameson SC; Thomson B; Collins MH; Wagoner LE; Freese DK; Beck LA; Boyce JA; Filipovich AH; Villanueva JM; Sutton SA; Assa'ad AH; Rothenberg ME
J Allergy Clin Immunol; 2004 Jan; 113(1):115-9. PubMed ID: 14699394
[TBL] [Abstract][Full Text] [Related]
10. Eosinophilic myositis with eosinophilic cellulitislike skin lesions. Association with increased serum levels of eosinophil cationic protein and interleukin-5.
Trüeb RM; Lübbe J; Torricelli R; Panizzon RG; Wüthrich B; Burg G
Arch Dermatol; 1997 Feb; 133(2):203-6. PubMed ID: 9041834
[TBL] [Abstract][Full Text] [Related]
11. [Dysregulation of cooperative interactions of immunocytes and eosinophils in the mechanism of development of eosinophilia in Opisthorhis felineus invasion].
Litvinova LS; Riazantseva NV; Novitskiĭ VV
Med Parazitol (Mosk); 2008; (3):13-7. PubMed ID: 18819423
[TBL] [Abstract][Full Text] [Related]
12. Conjunctival fibroblasts enhance the survival and functional activity of peripheral blood eosinophils in vitro.
Solomon A; Shmilowich R; Shasha D; Frucht-Pery J; Pe'er J; Bonini S; Levi-Schaffer F
Invest Ophthalmol Vis Sci; 2000 Apr; 41(5):1038-44. PubMed ID: 10752939
[TBL] [Abstract][Full Text] [Related]
13. Current strategies in the management of hypereosinophilic syndrome, including mepolizumab.
Schwartz LB; Sheikh J; Singh A
Curr Med Res Opin; 2010 Aug; 26(8):1933-46. PubMed ID: 20565230
[TBL] [Abstract][Full Text] [Related]
14. Anti-interleukin-5 therapy for asthma and hypereosinophilic syndrome.
Kay AB; Klion AD
Immunol Allergy Clin North Am; 2004 Nov; 24(4):645-66, vii. PubMed ID: 15474864
[TBL] [Abstract][Full Text] [Related]
15. Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study.
Kips JC; O'Connor BJ; Langley SJ; Woodcock A; Kerstjens HA; Postma DS; Danzig M; Cuss F; Pauwels RA
Am J Respir Crit Care Med; 2003 Jun; 167(12):1655-9. PubMed ID: 12649124
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-5 mRNA levels in blood and bone marrow mononuclear cells from patients with the idiopathic hypereosinophilic syndrome.
Satoh T; Sun L; Li MS; Spry CJ
Immunology; 1994 Oct; 83(2):308-12. PubMed ID: 7835952
[TBL] [Abstract][Full Text] [Related]
17. Montelukast reduces peripheral blood eosinophilia but not tissue eosinophilia or symptoms in a patient with eosinophilic gastroenteritis and esophageal stricture.
Daikh BE; Ryan CK; Schwartz RH
Ann Allergy Asthma Immunol; 2003 Jan; 90(1):23-7. PubMed ID: 12546333
[TBL] [Abstract][Full Text] [Related]
18. Eosinophilic gastroenteritis presenting with acute pancreatitis.
Maeshima A; Murakami H; Sadakata H; Saitoh T; Matsushima T; Tamura J; Karasawa M; Naruse T
J Med; 1997; 28(3-4):265-72. PubMed ID: 9355030
[TBL] [Abstract][Full Text] [Related]
19. Airway allergen exposure stimulates bone marrow eosinophilia partly via IL-9.
Sitkauskiene B; Rådinger M; Bossios A; Johansson AK; Sakalauskas R; Lötvall J
Respir Res; 2005 Apr; 6(1):33. PubMed ID: 15823208
[TBL] [Abstract][Full Text] [Related]
20. Mepolizumab: 240563, anti-IL-5 monoclonal antibody - GlaxoSmithKline, anti-interleukin-5 monoclonal antibody - GlaxoSmithKline, SB 240563.
Drugs R D; 2008; 9(2):125-30. PubMed ID: 18298130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
